<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Carbamazepine for chronic neuropathic pain and fibromyalgia in adults - Wiffen, PJ - 2014 | Cochrane Library</title> <meta content="Carbamazepine for chronic neuropathic pain and fibromyalgia in adults - Wiffen, PJ - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005451.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Carbamazepine for chronic neuropathic pain and fibromyalgia in adults - Wiffen, PJ - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005451.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005451.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Carbamazepine for chronic neuropathic pain and fibromyalgia in adults" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="pwiffen@oxfordsrs.org.uk" name="citation_author_email"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Eija A Kalso" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD005451.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/04/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005451.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005451.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005451.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; Carbamazepine [adverse effects, *therapeutic use]; Chronic Pain [*drug therapy, etiology]; Diabetic Neuropathies [*drug therapy]; Fibromyalgia [*drug therapy]; Neuralgia [drug therapy]; Randomized Controlled Trials as Topic; Stroke [complications]; Trigeminal Neuralgia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005451.pub3&amp;doi=10.1002/14651858.CD005451.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005451\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005451\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005451.pub3",title:"Carbamazepine for chronic neuropathic pain and fibromyalgia in adults",firstPublishedDate:"Apr 10, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005451.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005451.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005451.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005451.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005451.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005451.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005451.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005451.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005451.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005451.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8717 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005451.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/appendices#CD005451-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/table_n/CD005451StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/table_n/CD005451StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Carbamazepine for chronic neuropathic pain and fibromyalgia in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#CD005451-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#CD005451-cr-0003">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#CD005451-cr-0004">R Andrew Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information#CD005451-cr-0005">Eija A Kalso</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information/en#CD005451-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 April 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005451.pub3">https://doi.org/10.1002/14651858.CD005451.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005451-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005451-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005451-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005451-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005451-abs-0001" lang="en"> <section id="CD005451-sec-0001"> <h3 class="title" id="CD005451-sec-0001">Background</h3> <p>This is an update of a Cochrane review entitled 'Carbamazepine for acute and chronic pain in adults' published in Issue 1, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review considers the treatment of chronic neuropathic pain and fibromyalgia only, and adds no new studies. The update uses higher standards of evidence than the earlier review, which results in the exclusion of five studies that were previously included. </p> </section> <section id="CD005451-sec-0002"> <h3 class="title" id="CD005451-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy of carbamazepine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse events reported in the studies. </p> </section> <section id="CD005451-sec-0003"> <h3 class="title" id="CD005451-sec-0003">Search methods</h3> <p>We searched for relevant studies in MEDLINE, EMBASE and CENTRAL up to February 2014. Additional studies were sought from clinical trials databases, and the reference list of retrieved articles and reviews. </p> </section> <section id="CD005451-sec-0004"> <h3 class="title" id="CD005451-sec-0004">Selection criteria</h3> <p>Randomised, double blind, active or placebo controlled trials (RCTs) investigating the use of carbamazepine (any dose, by any route, and for at least two weeks' duration) for the treatment of chronic neuropathic pain or fibromyalgia, with at least 10 participants per treatment group. Participants were adults aged 18 and over. </p> </section> <section id="CD005451-sec-0005"> <h3 class="title" id="CD005451-sec-0005">Data collection and analysis</h3> <p>Two study authors independently extracted data on efficacy, adverse events, and withdrawals, and examined issues of study quality. Numbers needed to treat for an additional beneficial effect (NNT) or harmful effect (NNH) with 95% confidence intervals (CIs) were calculated from dichotomous data. </p> <p>We performed analysis using three tiers of evidence. First tier evidence derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention‐to‐treat analysis without imputation for dropouts, at least 200 participants in the comparison, at least 8 weeks' duration, parallel design), second tier from data that failed to meet one or more of these criteria and were considered at some risk of bias but with adequate numbers in the comparison, and third tier from data involving small numbers of participants that was considered very likely to be biased or used outcomes of limited clinical utility, or both. </p> </section> <section id="CD005451-sec-0006"> <h3 class="title" id="CD005451-sec-0006">Main results</h3> <p>Ten included studies (11 publications) enrolled 480 participants with trigeminal neuralgia, diabetic neuropathy, and post stroke pain. Nine studies used a cross‐over design, and one a parallel group design. Most of the studies were of short duration, lasting four weeks or less. </p> <p>No study provided first or second tier evidence for an efficacy outcome. Using third tier evidence, carbamazepine generally provided better pain relief than placebo in the three conditions studied, with some indication of pain improvement over mainly the short term, but with poorly defined outcomes, incomplete reporting, and in small numbers of participants. There were too few data in studies comparing carbamazepine with active comparators to draw any conclusions. </p> <p>In four studies 65% (113/173) of participants experienced at least one adverse event with carbamazepine, and 27% (47/173) with placebo; for every five participants treated, two experienced an adverse event who would not have done so with placebo. In eight studies 3% (8/268) of participants withdrew due to adverse events with carbamazepine, and none (0/255) with placebo. Serious adverse events were not reported consistently; rashes were associated with carbamazepine. Four deaths occurred in patients on carbamazepine, with no obvious drug association. </p> </section> <section id="CD005451-sec-0007"> <h3 class="title" id="CD005451-sec-0007">Authors' conclusions</h3> <p>Carbamazepine is probably effective in some people with chronic neuropathic pain, but with caveats. No trial was longer than four weeks, had good reporting quality, nor used outcomes equivalent to substantial clinical benefit. In these circumstances, caution is needed in interpretation, and meaningful comparison with other interventions is not possible. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005451-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005451-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005451-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005451-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005451-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005451-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005451-abs-0003" lang="en"> <h3>Carbamazepine for chronic neuropathic pain and fibromyalgia in adults</h3> <p>Neuropathic pain is pain coming from damaged nerves. It is different from pain messages carried along healthy nerves from damaged tissue (a fall, or cut, or arthritic knee). Neuropathic pain is treated by different medicines than pain from damaged tissue. Medicines like paracetamol or ibuprofen are not effective in neuropathic pain, while medicines that are sometimes used to treat depression or epilepsy can be very effective in some people. Our understanding of fibromyalgia (a condition of persistent, widespread pain and tenderness, sleep problems, and fatigue) is lacking, but fibromyalgia can respond to the same medicines as neuropathic pain. </p> <p>Carbamazepine was developed to treat epilepsy, but it is now used to treat various forms of chronic pain. We performed searches (up to February 2014) to look for clinical trials where carbamazepine was used to treat neuropathic pain or fibromyalgia. We found 10 studies involving 418 people involved in testing carbamazepine. Studies were not generally of very good quality. Most were very small, as well as of short duration. Studies lasting only one or two weeks are unhelpful when pain can last for years. </p> <p>There was not enough good quality evidence to say how well carbamazepine worked in any neuropathic pain condition. Pooling four small studies showed that it was better than placebo, but the result cannot be relied upon. There was not enough information from these studies to make any reliable comment on adverse events or harm. </p> <p>Carbamazepine is probably helpful for some people with chronic neuropathic pain. It is not possible to know beforehand who will benefit and who will not. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005451-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-sec-0146">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005451-sec-0084"></div> <h3 class="title" id="CD005451-sec-0085">Implications for practice</h3> <section id="CD005451-sec-0085"> <p>Carbamazepine is probably effective in some people with chronic neuropathic pain, but with major caveats. Only third tier evidence was available, which is subject to potentially major bias in favour of active therapy. No trial was longer than four weeks, or of good reporting quality, nor used outcomes equivalent to substantial clinical benefit. In these circumstances, caution is needed in interpretation, and meaningful comparison with other interventions is not possible. An overview of antiepileptics in neuropathic pain and fibromyalgia concluded that, among antiepileptic drugs, clinical trial evidence supports only the use of gabapentin and pregabalin in some neuropathic pain conditions (painful diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain) and fibromyalgia (Wiffen 2013b). </p> <p>The use of carbamazepine in neuropathic pain has stood the test of time in the clinic, but carbamazepine usually does not now feature in treatment algorithms, other than for the treatment of trigeminal neuralgia. Current guidance in the UK states 'Despite the lack of trial evidence, it is perceived by clinicians to be efficacious. Further research should be conducted as described in the table below.' (<a href="./references#CD005451-bbs2-0086" title="Neuropathic pain – pharmacological management. NICE clinical guideline 173November 2013. ">NICE 2013</a>) </p> <p>Medical students are often taught that a positive response to carbamazepine is 'diagnostic' for trigeminal neuralgia. Even the suspect evidence we have indicates that this is not the case, with perhaps just over half of participants with trigeminal neuralgia having a good response to carbamazepine. Clinically it appears that trigeminal neuralgia can become refractory to carbamazepine. </p> <p>The usual clinical decision for chronic neuropathic pain is a choice between antidepressant and antiepileptic as first‐line treatment, and there is insufficient evidence to support the use of carbamazepine as first line. In addition the need for laboratory monitoring and significant drug interactions with the use of carbamazepine have discouraged the use of carbamazepine with the emergence of newer antiepileptic drugs, such as gabapentin and pregabalin. </p> </section> <h3 class="title" id="CD005451-sec-0086">Implications for research</h3> <section id="CD005451-sec-0086"> <p>This review shows that there is still a need for large, high quality, long duration studies using sensible outcomes to establish relative effectiveness of different antiepileptics in chronic pain syndromes, and for comparisons of other treatments such as antidepressants with antiepileptics; appropriate trial designs have been suggested for this (<a href="./references#CD005451-bbs2-0075" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , et al. for the ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: An approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2009;Sept 10:Epub ahead of print. [DOI: 10.1016/j.pain.2009.08.007] ">Moore 2009c</a>). The usefulness of such studies would be increased greatly by improvements in the quality of reporting, and particularly by use of clinically important end points rather than undefined improvement. Enriched enrolment randomised withdrawal studies have real potential (<a href="./references#CD005451-bbs2-0065" title="McQuayHJ , DerryS , MooreRA , PoulainP , LegoutV . Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain2008;135(3):217‐20. [DOI: 10.1016/j.pain.2008.01.014] ">McQuay 2008</a>). </p> <p>For carbamazepine the particular interest lies in treating trigeminal neuralgia. For this condition, for all interventions, there have been only a handful of good quality studies reported. The major implication for research is therefore for trigeminal neuralgia as a specific condition, and using carbamazepine as an historically useful medicine to understand the parameters around the conduct of successful clinical trials in a debilitating and often poorly responding condition. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005451-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005451-sec-0029"></div> <div class="table" id="CD005451-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with placebo for chronic neuropathic pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: oral carbamazepine (</b> 100 mg to 2400 mg daily<b>)</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNH and/or relative effect (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> and studies</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Substantial" benefit</p> <p>At least 50% reduction in pain or equivalent</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>608 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.5 (3.4 to 12)</p> <p>NNT 1.9 (1.6 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188 participants,</p> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed conditions and doses, small studies of short duration, imputation not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Moderate" benefit</p> <p>At least 30% reduction in pain</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion below 30/100 mm on VAS</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient Global Impression of Change much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>270 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>660 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.4 (1.9 to 3.2)</p> <p>NNH 2.6 (2.1 to 3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346 participants,</p> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over studies</p> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse event withdrawals</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>30 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523 participants,</p> <p>8 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over studies</p> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 participants,</p> <p>2 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 participants</p> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>NNT: number needed to treat for an additional beneficial effect: NNH: number needed to treat for an additional harmful effect; RR: risk ratio; VAS: visual analogue scale. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005451-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-sec-0111">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD005451-sec-0030"></div> <p>This updated review was originally published in <i>The Cochrane Library</i> as 'Anticonvulsant drugs for acute and chronic pain' (<a href="./references#CD005451-bbs2-0113" title="WiffenP , CollinsS , McQuayH , CarrollD , JadadA , MooreA . Anticonvulsantdrugs for acute and chronic pain. Cochrane Database of Systematic Reviews2000, Issue 3. [CENTRAL: CD001133] ">Wiffen 2000</a>). At the third update in 2003 (<a href="./references#CD005451-bbs2-0114" title="WiffenP , CollinsS , McQuayH , CarrollD , JadadA , MooreA . Anticonvulsantdrugs for acute and chronic pain. Cochrane Database of Systematic Reviews2003, Issue 3. [CENTRAL: CD001133] ">Wiffen 2003</a>), 12 new included studies were identified mainly of the newer antiepileptics (anticonvulsants) gabapentin and lamotrigine. In total the included studies provided data on six different medicines used in at least six identified neuropathic pain conditions. Issues of dose response and trial design added to the complexity. A decision was therefore taken to split that review into a number of smaller reviews each covering one medicine (chemical entity). In 2010 a review of carbamazepine for acute and chronic pain was published, and in 2011 the authors reviewed the literature and concluded that there were unlikely to be any new studies, so the review was marked as stable (<a href="./references#CD005451-bbs2-0116" title="WiffenPJ , DerryS , MooreRA , McQuayHJ . Carbamazepine for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD005451.pub2] ">Wiffen 2011a</a>). </p> <p>The decision to update it now, and concentrate on chronic neuropathic pain and fibromyalgia, was made because there have been more advances in the rigour with which we assess studies and report data, and in order to conform with other reviews in the series on neuropathic pain and fibromyalgia. In particular we consider study size and duration, outcomes reported, and method of imputation for withdrawals, and report results in three tiers according to outcome and freedom from known sources of bias. We wanted to bring this review in line with a template protocol so that it can be easily included in overview of antiepileptics for chronic neuropathic pain and fibromyalgia in adults (<a href="./references#CD005451-bbs2-0104" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013a</a>). Reviews of clonazepam (<a href="./references#CD005451-bbs2-0034" title="CorriganR , DerryS , WiffenPJ , MooreRA . Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2] ">Corrigan 2012</a>), gabapentin (<a href="./references#CD005451-bbs2-0080" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 201, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a>), lacosamide (<a href="./references#CD005451-bbs2-0048" title="HearnL , DerryS , MooreRA . Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009318.pub2] ">Hearn 2012</a>), lamotrigine (<a href="./references#CD005451-bbs2-0105" title="WiffenPJ , DerryS , MooreRA . Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD006044.pub4] ">Wiffen 2013b</a>), oxcarbazepine (<a href="./references#CD005451-bbs2-0110" title="ZhouM , ChenN , HeL , YangM , ZhuC , WuF . Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD007963.pub2] ">Zhou 2013</a>), phenytoin (<a href="./references#CD005451-bbs2-0029" title="BirseF , DerryS , MooreRA . Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2] ">Birse 2012</a>), pregabalin (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>), topiramate (<a href="./references#CD005451-bbs2-0106" title="WiffenPJ , DerryS , LunnMP , MooreRA . Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008314.pub3] ">Wiffen 2013c</a>), and valproic acid (<a href="./references#CD005451-bbs2-0043" title="GillD , DerryS , WiffenPJ , MooreRA . Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2] ">Gill 2011</a>) have been completed. All the reviews analyse results according to the particular conditions in which they have been studied, and it is expected that in future updates fibromyalgia, at least, will become the subject of separate reviews. </p> <p>The aim is for all our reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD005451-bbs2-0076" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010a</a>; <a href="./references#CD005451-bbs2-0082" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012b</a>; <a href="./appendices#CD005451-sec-0090">Appendix 1</a>). A Cochrane review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia) (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>). This indicates that different neuropathic pain conditions should be treated separately from one another, and that pooling should not be done unless there are good grounds for doing so. While fibromyalgia is considered to have a different aetiology from chronic neuropathic pain, it is a condition that responds to the same therapies. Because of limitations in the number of available clinical trials, it is convenient to consider fibromyalgia together with neuropathic pain. We make no presumption to pool data across individual neuropathic pain conditions or fibromyalgia, but will consider each condition separately. </p> <p>The small amount of information in the 2011 review relating to acute pain has been moved to <a href="./appendices#CD005451-sec-0091">Appendix 2</a>. </p> <section id="CD005451-sec-0031"> <h3 class="title" id="CD005451-sec-0031">Description of the condition</h3> <p>The 2011 International Association for the Study of Pain definition of <i>neuropathic pain</i> is "pain caused by a lesion or disease of the somatosensory system" (<a href="./references#CD005451-bbs2-0054" title="JensenTS , BaronR , HaanpääM , KalsoE , LoeserJD , RiceAS , et al. A new definition of neuropathic pain. Pain2011; Vol. 152, issue 10:2204‐5. [DOI: 10.1016/j.pain.2011.06.017] ">Jensen 2011</a>) based on an earlier consensus meeting (<a href="./references#CD005451-bbs2-0102" title="TreedeRD , JensenTS , CampbellJN , CruccuG , DostrovskyJO , GriffinJW , et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology2008;70(18):1630‐5. ">Treede 2008</a>). Neuropathic pain may be caused by nerve damage, but is often followed by changes in the central nervous system (CNS) (<a href="./references#CD005451-bbs2-0067" title="MoissetX , BouhassiraD . Brain imaging of neuropathic pain. Neuroimaging2007;37(Suppl 1):S80‐8. ">Moisset 2007</a>). It is complex, and neuropathic pain features can be found in patients with joint pain (<a href="./references#CD005451-bbs2-0094" title="SoniA , BatraR , GwilymS , SpectorT , HartD , ArdenN , et al. Neuropathic features of joint pain: a community‐based study. Arthritis &amp; Rheumatism2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962] ">Soni 2013</a>). </p> <p><i>Fibromyalgia</i> is defined as widespread pain for longer than three months with pain on palpation at 11 or more of 18 specified tender points (<a href="./references#CD005451-bbs2-0107" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis and Rheumatism1990;33:160‐72. ">Wolfe 1990</a>), and is frequently associated with other symptoms such as poor sleep, fatigue, and depression. More recently, a definition of fibromyalgia has been proposed based on symptom severity and the presence of widespread pain (<a href="./references#CD005451-bbs2-0108" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research2010;62:600‐10. [DOI: 10.1002/acr.20140] ">Wolfe 2010</a>). The cause, or causes, are not well understood, but it has features in common with neuropathic pain, including changes in the CNS. Moreover, patients with neuropathic pain and those with fibromyalgia experience similar sensory phenomena (<a href="./references#CD005451-bbs2-0059" title="KoroschetzJ , RehmSE , GockelU , BroszM , FreynhagenR , TölleTR , et al. Fibromyalgia and neuropathic pain－differences and similarities: a comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology2011;11:55. [DOI: 10.1186/1471‐2377‐11‐55] ">Koroschetz 2011</a>), and peripheral nerve fibre changes seen in neuropathic pain also occur in fibromyalgia (<a href="./references#CD005451-bbs2-0089" title="OaklanderAL , HerzogZD , DownsHM , KleinMM . Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain2013;154(11):2310‐6. [DOI: 10.1016/j.pain.2013.06.001] ">Oaklander 2013</a>; <a href="./references#CD005451-bbs2-0111" title="ÜçeylerN , ZellerD , KahnAK , KewenigS , Kittel‐SchneiderS , SchmidA , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain2013;136(6):1857‐67. [DOI: 10.1093/brain/awt053] ">Üçeyler 2013</a>). Many people with these conditions are significantly disabled with moderate or severe pain for many years. </p> <p>In primary care in the United Kingdom (UK), the incidences per 100,000 person‐years' observation have been reported as 28 (95% CI 27 to 30) for postherpetic neuralgia, 27 (26 to 29) for trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain, and 21 (20 to 22) for painful diabetic neuropathy (<a href="./references#CD005451-bbs2-0046" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice2008;9:26. [DOI: 10.1186/1471‐2296‐9‐26] ">Hall 2008</a>). Estimates vary between studies, often because of small numbers of cases. The incidence of trigeminal neuralgia has been estimated at 4 in 100,000 per year (<a href="./references#CD005451-bbs2-0055" title="KatusicS , WilliamsDB , BeardCM , BergstralhEJ , KurlandLT . Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology1991;10:276‐81. ">Katusic 1991</a>; <a href="./references#CD005451-bbs2-0091" title="RappaportZH , DevorM . Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain1994;56:127‐38. [DOI: 10.1016/0304‐3959(94)90086‐8] ">Rappaport 1994</a>), while more recently, a study of facial pain in The Netherlands found incidences per 100,000 person‐years of 12.6 for trigeminal neuralgia and 3.9 for postherpetic neuralgia (<a href="./references#CD005451-bbs2-0058" title="KoopmanJS , DielemanJP , HuygenFJ , deMosM , MartinCG , SturkenboomMC . Incidence of facial pain in the general population. Pain2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] ">Koopman 2009</a>). A systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as painful diabetic neuropathy, can be more common, with prevalence rates up to 400 per 100,000 person‐years (<a href="./references#CD005451-bbs2-0064" title="McQuayHJ , SmithLA , MooreRA . Chronic Pain. In: StevensA , RafteryJ , MantJ , SimpsonS editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. ">McQuay 2007</a>). The prevalence of neuropathic pain was reported as being 3.3% in Austria (<a href="./references#CD005451-bbs2-0045" title="GustorffB , DornerT , LikarR , GrisoldW , LawrenceK , SchwarzF , et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica2008;52(1):132‐6. [DOI: 10.1111/j.1399‐6576.2007.01486.x] ">Gustorff 2008</a>), 6.9% in France (<a href="./references#CD005451-bbs2-0030" title="BouhassiraD , Lantéri‐MinetM , AttalN , LaurentB , TouboulC . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] ">Bouhassira 2008</a>) and as high as 8% in the UK (<a href="./references#CD005451-bbs2-0101" title="TorranceN , SmithBH , BennettMI , LeeAJ . The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. Journal of Pain2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] ">Torrance 2006</a>), and about 7% in a systematic review of studies published since 2000 (<a href="./references#CD005451-bbs2-0083" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050] ">Moore 2013a</a>). The incidence of some forms of neuropathic pain, such as diabetic neuropathy and postherpetic neuralgia, is increasing (<a href="./references#CD005451-bbs2-0047" title="HallGC , MorantSV , CarrollD , GabrielZL , McQuayHJ . An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice2013;14:28. [DOI: 10.1186/1471‐2296‐14‐28] ">Hall 2013</a>). Fibromyalgia is common, especially in women, with an all‐age prevalence of 12%, and a female to male ratio of 6:1 (<a href="./references#CD005451-bbs2-0063" title="McNallyJD , MathesonDA , BakowskyVS . The epidemiology of self‐reported fibromyalgia in Canada. Chronic Diseases in Canada2006;27(1):9‐16. ">McNally 2006</a>). </p> <p>Neuropathic pain and fibromyalgia are known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. A multidisciplinary approach is now advocated, with pharmacological interventions being combined with physical and/or cognitive interventions. Conventional analgesics are usually not effective. Some patients with neuropathic pain may derive some benefit from topical lidocaine patch or low concentration topical capsaicin, although evidence of benefit is uncertain (<a href="./references#CD005451-bbs2-0036" title="DerryS , MooreRA . Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD010111] ">Derry 2012</a>; <a href="./references#CD005451-bbs2-0056" title="KhaliqW , AlamS , PuriN . Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2] ">Khaliq 2007</a>). High concentration topical capsaicin may benefit some patients with postherpetic neuralgia (<a href="./references#CD005451-bbs2-0037" title="DerryS , Sven‐RiceA , ColeP , TanT , MooreRA . Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] ">Derry 2013</a>). Treatment is more usually by so‐called unconventional analgesics such as antidepressants like duloxetine and amitriptyline (<a href="./references#CD005451-bbs2-0062" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2] ">Lunn 2009</a>; <a href="./references#CD005451-bbs2-0081" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] ">Moore 2012a</a>; <a href="./references#CD005451-bbs2-0097" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology2008;8:29. [DOI: 10.1186/1471‐2377‐8‐29] ">Sultan 2008</a>) or antiepileptics like gabapentin or pregabalin (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>; <a href="./references#CD005451-bbs2-0080" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 201, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a>). The proportion of patients who achieve worthwhile pain relief (typically defined as at least 50% pain intensity reduction (<a href="./references#CD005451-bbs2-0084" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs－'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013b</a>)) is small, typically 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNTs) usually between 4 and 10. </p> </section> <section id="CD005451-sec-0032"> <h3 class="title" id="CD005451-sec-0032">Description of the intervention</h3> <p>Carbamazepine was first marketed in the early 1960s to treat trigeminal neuralgia, with its antiepileptic effects recognised soon afterwards. It is licensed in the United Kingdom and United States of America for paroxysmal pain of trigeminal neuralgia (dosage up to 1600 mg daily), but has been used off‐label for other types of neuropathic pain. It is usually prescribed as a tablet, but chewable tablet, liquid, and suppository formulations are manufactured. </p> <p>Antiepileptic drug use is not without risk: serious adverse effects have been reported, including deaths from haematological reactions (blood dyscrasias; <a href="./references#CD005451-bbs2-0098" title="SweetmanS (Editor) . Martindale: The Complete Drug Reference. 4th Edition. London: Pharmaceutical Press, 2005:353‐358. [ISBN 0 85369 550 4] ">Sweetman 2005</a>), and life‐threatening cutaneous problems (<a href="./references#CD005451-bbs2-0032" title="ChungWH , HungSI , ChenYT . Genetic predisposition of life‐threatening antiepileptic‐induced skin reactions. Expert Opinion on Drug Safety2010;9:15‐21. ">Chung 2010</a>; <a href="./references#CD005451-bbs2-0060" title="Kulkantrakorn K. Tassaneeyakul W. Tiamkao S. Jantararoungtong T. Prabmechai N. VannaprasahtS , et al. HLA‐B*1502 strongly predicts carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Practice2012;12(3):202‐8. [DOI: 10.1111/j.1533‐2500.2011.00479.x] ">Kulkantrakorn 2012</a>). Carbamazepine is also known to stimulate synthesis of certain enzymes, which can interfere with other drug therapies (e.g. anticoagulants, antiretrovirals, statins, antihypertensives) causing clinical problems, particularly at initiation and withdrawal (<a href="./references#CD005451-bbs2-0031" title="BrodieMJ , MintzerS , PackAM , GidalBE , VechtCJ , SchmidtD . Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia2013;54(1):11‐27. [DOI: 10.1111/j.1528‐1167.2012.03671.x] ">Brodie 2013</a>). The most common adverse effects are impaired mental and motor function, which may limit clinical use, particularly in older people (<a href="./references#CD005451-bbs2-0044" title="Grahame‐SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford Textbook of Clinical Pharmacology and Drug Therapy. 2nd Edition. Oxford: Oxford University Press, 1992. ">Grahame‐Smith 1992</a>; <a href="./references#CD005451-bbs2-0090" title="RallTW , SchleiferLS . Drugs effective in the therapy of the epilepsies. In: GoodmanLS , GilmanA , RallTW , NiesAS , TaylorP editor(s). The pharmacological basis of therapeutics. 8th Edition. Toronto: McGraw‐Hill, 1992:436‐62. ">Rall 1992</a>; <a href="./references#CD005451-bbs2-0098" title="SweetmanS (Editor) . Martindale: The Complete Drug Reference. 4th Edition. London: Pharmaceutical Press, 2005:353‐358. [ISBN 0 85369 550 4] ">Sweetman 2005</a>). </p> </section> <section id="CD005451-sec-0033"> <h3 class="title" id="CD005451-sec-0033">How the intervention might work</h3> <p>Pain that manifests in different diseases may operate through common mechanisms, but the same symptom in two patients may be caused by different mechanisms. It is therefore impossible to predict the mechanisms responsible for an individual's pain based on the aetiology of the neuropathy or on the distribution or nature of symptoms (<a href="./references#CD005451-bbs2-0109" title="WoolfCJ , MannionR . Neuropathic pain, aetiology, symptoms, mechanisms, and management. Lancet1999;353:1959‐64. ">Woolf 1999</a>). Carbamazepine stabilizes the inactivated state of voltage‐gated sodium channels, so that fewer of these channels are available to open, and brain cells are less excitable and less likely to fire (<a href="./references#CD005451-bbs2-0027" title="AmbrósioAF , SilvaAP , MalvaJO , Soares‐da‐SilvaP , CarvalhoAP , CarvalhoCM . Carbamazepine inhibits L‐type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology1999;38(9):1349‐59. [DOI: 10.1016/S0028‐3908(99)00058‐1] ">Ambrósio 1999</a>; <a href="./references#CD005451-bbs2-0085" title="MorissetV , DavisJB , TateSN . Mechanism of action of anticonvulsants as analgesic drugs. In: McMahonSB , KoltenburgM , TraceyI , TurkDC editor(s). Wall &amp; Melzack's Textbook of Pain. 6. Philadelphia: Elsevier Saunders, 2013:491‐9. [ISBN: 978‐0‐7020‐4059‐7] ">Morisset 2013</a>). </p> </section> <section id="CD005451-sec-0034"> <h3 class="title" id="CD005451-sec-0034">Why it is important to do this review</h3> <p>The standards used to assess evidence in chronic pain trials have changed substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy (<a href="./appendices#CD005451-sec-0090">Appendix 1</a>). The most important change is the move from using average pain scores, or average change in pain scores, to using the number of patients who have a large decrease in pain (by at least 50%); this level of pain relief has been shown to correlate with improvements in comorbid symptoms, function, and quality of life. These standards are set out in the reference guide for pain studies (<a href="./references#CD005451-bbs2-0028" title="PaPaS author and referee guidance. http://papas.cochrane.org/papas‐documents (accessed 1 August 2013). ">AUREF 2012</a>) and reflect what patients with chronic pain want from treatment (<a href="./references#CD005451-bbs2-0083" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2013;March 6:Epub ahead of print. [DOI: 10.1111/papr.12050] ">Moore 2013a</a>). </p> <p>This Cochrane review will assess evidence in ways that make both statistical and clinical sense, and will use developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD005451-bbs2-0076" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010a</a>). Trials included and analysed will need to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc), and size (ideally at least 500 participants in a comparison in which the (NNT) is four or more (<a href="./references#CD005451-bbs2-0068" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything－large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>)). </p> <p>Carbamazepine has been used to treat some types of neuropathic pain for about 50 years. It is important to know its place in the range of drugs used to treat the various types of neuropathic pain. This updated review brings the evidence for carbamazepine into line with that for other medicines used in these conditions, and will form part of an overview of antiepileptic drugs for chronic neuropathic pain and fibromyalgia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005451-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-sec-0116">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005451-sec-0035"></div> <p>To assess the analgesic efficacy of carbamazepine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse events reported in the studies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005451-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-sec-0117">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005451-sec-0036"></div> <section id="CD005451-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005451-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included studies if they were randomised controlled trials (RCTs) with at least 10 participants per treatment group and double‐blind (participant and observers) assessment of participant‐reported outcomes, following two weeks of treatment or longer, although the emphasis of the review is on studies of eight weeks or longer. Full journal publication was required, with the exception of extended abstracts of otherwise unpublished clinical trials (for example detailed information from PDFs of posters that typically include all important details of methodology used and results obtained). We did not include short abstracts (usually meeting reports with inadequate or no reporting of data). We excluded studies of experimental pain, case reports, and clinical observations. </p> <p>Migraine and headache studies previously included in an earlier version of this review were excluded (<a href="./references#CD005451-bbs2-0113" title="WiffenP , CollinsS , McQuayH , CarrollD , JadadA , MooreA . Anticonvulsantdrugs for acute and chronic pain. Cochrane Database of Systematic Reviews2000, Issue 3. [CENTRAL: CD001133] ">Wiffen 2000</a>). This subject is being dealt with in greater depth by the Cochrane Pain, Palliative Care and Supportive Care Review Group. </p> </section> <section id="CD005451-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adult participants aged 18 years and above. Participants could have one or more of a wide range of chronic neuropathic pain conditions including (but not limited to): </p> <p> <ul id="CD005451-list-0001"> <li> <p>painful diabetic neuropathy (PDN);</p> </li> <li> <p>postherpetic neuralgia (PHN);</p> </li> <li> <p>trigeminal neuralgia;</p> </li> <li> <p>phantom limb pain;</p> </li> <li> <p>postoperative or traumatic neuropathic pain;</p> </li> <li> <p>complex regional pain syndrome (CRPS) Type II;</p> </li> <li> <p>cancer‐related neuropathy;</p> </li> <li> <p>HIV‐neuropathy;</p> </li> <li> <p>spinal cord injury;</p> </li> </ul> </p> <p>or</p> <p> <ul id="CD005451-list-0002"> <li> <p>fibromyalgia;</p> </li> <li> <p>complex regional pain syndrome (CRPS) Type I.</p> </li> </ul> </p> <p>We also included studies of participants with more than one type of neuropathic pain. We analysed results according to the primary condition. </p> </section> <section id="CD005451-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Carbamazepine in any dose, by any route, administered for the relief of neuropathic pain or fibromyalgia, and compared to placebo, no intervention or any other active comparator. We did not include studies using carbamazepine to treat pain resulting from the use of other drugs. </p> </section> <section id="CD005451-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD005451-bbs2-0039" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain2008;9(2):105‐21. ">Dworkin 2008</a>). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These outcomes concentrate on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain intensity not worse than mild (<a href="./references#CD005451-bbs2-0088" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x] ">O'Brien 2010</a>). </p> <p>We include a Summary of findings table as set out in the Cochrane Pain, Palliative and Supportive Care Group author guide (<a href="./references#CD005451-bbs2-0028" title="PaPaS author and referee guidance. http://papas.cochrane.org/papas‐documents (accessed 1 August 2013). ">AUREF 2012</a>). The Summary of findings table includes outcomes of at least 30% and at least 50% pain intensity reduction, PGIC, at least one adverse event, adverse event withdrawals, serious adverse events and death. </p> <section id="CD005451-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005451-list-0003"> <li> <p>Participant‐reported pain intensity reduction of 30% or greater.</p> </li> <li> <p>Participant‐reported pain intensity reduction of 50% or greater.</p> </li> <li> <p>Participant‐reported global impression of clinical change (PGIC) much or very much improved. </p> </li> <li> <p>Participant‐reported global impression of clinical change (PGIC) very much improved.</p> </li> </ol> </p> </section> <section id="CD005451-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005451-list-0004"> <li> <p>Any pain‐related outcome indicating some improvement.</p> </li> <li> <p>Withdrawals due to lack of efficacy.</p> </li> <li> <p>Participants experiencing any adverse event.</p> </li> <li> <p>Participants experiencing any serious adverse event.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> <li> <p>Specific adverse events, particularly somnolence and dizziness.</p> </li> </ol> </p> <p>These outcomes are not eligibility criteria for this review, but are outcomes of interest within whichever studies are included. </p> </section> </section> </section> <section id="CD005451-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>Studies were identified by several methods.</p> <section id="CD005451-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For the earlier review, RCTs of antiepileptics in acute, chronic or cancer pain were identified by searching MEDLINE (originally via Silver Platter, then Ovid) from 1966 to June 2010, EMBASE 1994 to Dec 2009, SIGLE 1980 to July 1999, and CENTRAL (Issue 4, 2010). </p> <p>When the review was split in to individual drugs, this search strategy was narrowed to include carbamazepine only. <a href="./appendices#CD005451-sec-0093">Appendix 3</a> has the search strategies for CENTRAL, MEDLINE and EMBASE. </p> <p>For this update we searched:</p> <p> <ul id="CD005451-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, 2014 Issue 1 in <i>The Cochrane Library</i>); </p> </li> <li> <p>MEDLINE (via Ovid) (January 2010 to 7 February 2014);</p> </li> <li> <p>EMBASE (via Ovid) (January 2010 to 7 February 2014);</p> </li> <li> <p>PhRMA clinical study results database (clinicaltrials.gov) to 7 February 2014;</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch) to 7 February 2014 </p> </li> </ul> </p> </section> <section id="CD005451-sec-0046"> <h4 class="title">Searching other resources</h4> <p>Additional studies were identified from the reference list of the retrieved papers. In the first version, a letter was sent to the first author of a report for further information on their published report (method of randomisation, double blinding, outcome measures and dropouts) and to ask if they knew of any other studies which met our inclusion criteria, either undertaken by them or by other investigators. In addition, 41 medical journals were hand searched, chosen from the 50 with the highest number of reports in MEDLINE, and nine specialist journals which were either not on that list or were not indexed (<a href="./references#CD005451-bbs2-0052" title="Jadad‐BecharaAR . Meta‐analysis of randomised clinical trials in pain relief [DPhil thesis]. Oxford: Balliol College, University of Oxford, 1994. ">Jadad 1994</a>). The search process included volumes published between 1950 and 1990. No further hand searching has been undertaken as the key journals are now being searched by the Cochrane Collaboration. </p> <p>In an earlier version of this review data were requested from 19 authors but only one (<a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>) was able to supply information relevant to this review. In the two updates, no further attempt was made to contact authors. </p> </section> </section> <section id="CD005451-sec-0047"> <h3 class="title" id="CD005451-sec-0047">Data collection and analysis</h3> <section id="CD005451-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently read the titles and abstracts of all studies identified by the search, and the full text of all potentially relevant studies. Agreement on eligibility was reached by discussion. We did not anonymise the studies in any way before assessment. </p> </section> <section id="CD005451-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted data using a standard data extraction form, and agreed data before entry into RevMan (<a href="./references#CD005451-bbs2-0092" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) or any other analysis method. Data extracted included information about the pain condition and number of participants treated, drug and dosing regimen, study design, study duration and follow up, analgesic outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, or a serious adverse event). </p> </section> <section id="CD005451-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We independently scored each study for quality using a three‐item scale (<a href="./references#CD005451-bbs2-0053" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , McQuayHJ . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. ">Jadad 1996</a>) and agreed a 'consensus' score for each study. Scores of two and below have been associated with greater estimates of efficacy than studies of higher quality (<a href="./references#CD005451-bbs2-0057" title="KhanKS , DayaS , JadadA . The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine1996;156(6):661‐6. ">Khan 1996</a>). Quality scores were not used to weight the results in any way. </p> <p>We used the 'Risk of bias' tool to assess the likely impact on the strength of the evidence of various study characteristics relating to methodological quality (randomisation, allocation concealment, blinding, freedom from selective reporting), study validity (duration, outcome reporting, and handling of missing data), and size (<a href="./references#CD005451-bbs2-0076" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010a</a>). </p> <p>Two review authors independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005451-bbs2-0050" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ul id="CD005451-list-0006"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how this was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (&lt; 10% of participants did not complete the study and/or used ‘baseline observation carried forward’ analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD005451-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Relative risk (or risk ratio, RR) was used to establish statistical difference. Numbers needed to treat (NNT) and pooled percentages were used as absolute measures of benefit or harm. </p> <p>The following terms are used to describe adverse outcomes in terms of harm or prevention of harm: </p> <p> <ul id="CD005451-list-0007"> <li> <p>When significantly fewer adverse outcomes occurred with carbamazepine than with control (placebo or active) we use the term the number needed to treat to prevent one event (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with carbamazepine compared with control (placebo or active) we use the term the number needed to harm or cause one event (NNH). </p> </li> </ul> </p> </section> <section id="CD005451-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The control treatment arm would be split between active treatment arms in a single study if the active treatment arms were not combined for analysis. </p> </section> <section id="CD005451-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analysis wherever possible. The ITT population consisted of participants who were randomised, took the assigned study medication and provided at least one post‐baseline assessment. Missing participants were assigned zero improvement (baseline observation carried forward, BOCF) where this could be done. We were aware that imputation methods might be problematical and examined trial reports for information about them. </p> </section> <section id="CD005451-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to deal with clinical heterogeneity by combining studies that examined similar conditions. We assessed statistical heterogeneity visually (<a href="./references#CD005451-bbs2-0061" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107:224‐33. ">L'Abbe 1987</a>) and with the use of the I<sup>2</sup> statistic. </p> </section> <section id="CD005451-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous data of known utility (<a href="./references#CD005451-bbs2-0074" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2009;Online:April 12. [DOI: 10.1136/ard.2009.107805] ">Moore 2009b</a>). The review did not depend on what authors of the original studies chose to report or not report, though clearly there were difficulties with studies failing to report any dichotomous results. Continuous data, which probably poorly reflect efficacy and utility, were extracted and used only when useful for illustrative purposes. </p> <p>We undertook no statistical assessment of publication bias.</p> <p>We looked for evidence of possible enrichment, either complete or partial, in enrolment of participants into the studies. Enrichment typically means including participants known to respond to a therapy, and excluding those known not to respond, or to suffer unacceptable adverse effects, though for gabapentin no significant effects have been shown from partial enrichment (<a href="./references#CD005451-bbs2-0095" title="StraubeS , DerryS , McQuayHJ , MooreRA . Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology2008;66(2):266‐75. [DOI: 10.1111/j.1365‐2125.2008.03200.x] ">Straube 2008</a>). Enriched enrolment randomised withdrawal studies, known to produce higher estimates of efficacy, would not be pooled (<a href="./references#CD005451-bbs2-0065" title="McQuayHJ , DerryS , MooreRA , PoulainP , LegoutV . Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain2008;135(3):217‐20. [DOI: 10.1016/j.pain.2008.01.014] ">McQuay 2008</a>). </p> </section> <section id="CD005451-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We analysed data for each painful condition in three tiers, according to outcome and freedom from known sources of bias. </p> <p> <ul id="CD005451-list-0008"> <li> <p>The first tier uses data meeting current best standards, where studies report the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of last observation carried forward (LOCF) or other imputation method for dropouts, report an intention‐to‐treat (ITT) analysis, last eight or more weeks, have a parallel‐group design, and have at least 200 participants (preferably at least 400) in the comparison (<a href="./references#CD005451-bbs2-0076" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010a</a>; <a href="./references#CD005451-bbs2-0082" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012b</a>). These top‐tier results are reported first. </p> </li> <li> <p>The second tier uses data from at least 200 participants but where one or more of the above conditions is not met (for example reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks). </p> </li> <li> <p>The third tier of evidence relates to data from fewer than 200 participants, or where there are expected to be significant problems because, for example, of very short duration studies of less than four weeks, where there is major heterogeneity between studies, or where there are shortcomings in allocation concealment, attrition, or incomplete outcome data. For this third tier of evidence, no data synthesis is reasonable, and may be misleading, but an indication of beneficial effects might be possible </p> </li> </ul> </p> </section> <section id="CD005451-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned for all analyses to be according to individual painful conditions, because placebo response rates with the same outcome can vary between conditions, as can the drug‐specific effects (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>). We also planned subgroup analysis for dose of carbamazepine and duration of study. </p> </section> <section id="CD005451-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned no sensitivity analyses because the evidence base was known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005451-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005451-sec-0059"></div> <section id="CD005451-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD005451-sec-0061"> <h4 class="title">Results of the search</h4> <p>New searches to February 2014 identified two potentially relevant studies (<a href="./references#CD005451-bbs2-0020" title="SalinasFA , LugoLH , GarcíaHI . Efficacy of early treatment with carbamazepine in prevention of neuropathic pain in patients with spinal cord injury. American Journal of Physical Medicine and Rehabilitaion2012;91(12):1020‐7. [DOI: 10.1097/PHM.0b013e3182643c85] ">Salinas 2012</a>; <a href="./references#CD005451-bbs2-0021" title="ShaikhS , YaacobHB , Abd RahmanRB . Lamotrigine for trigeminal neuralgia: efficacy and safety in comparison with carbamazepine. Journal of the Chinese Medical Association2011;74(6):243‐9. [DOI: 10.1016/j.jcma.2011.04.002] ">Shaikh 2011</a>), but neither satisfied our inclusion criteria, so there were no new included studies in this update. Two studies that were identified in an earlier search remain unavailable (<a href="./references#CD005451-bbs2-0025" title="BadranAM , AlyMA , SousES . A clinical trial of carbamazepine in the symptomatic treatment of diabetic peripheral neuropathy. The Journal of the Egyptian Medical Association1975;58(11‐12):627‐631. ">Badran 1975</a>; <a href="./references#CD005451-bbs2-0026" title="LiebelJ . Results of a double blind trial comparing oxcarbazepine vs carbamazepine in newly diagnosed, untreated patients with trigeminal neuralgia. Journal of the Neurological Sciences2001;187:S5. ">Liebel 2001</a>). <a href="#CD005451-fig-0001">Figure 1</a> shows the flow diagram for included studies. </p> <div class="figure" id="CD005451-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005451-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005451-sec-0062"> <h4 class="title">Included studies</h4> <p>This updated review includes 10 studies (11 publications) with 480 participants, 414 of whom were randomised to receive carbamazepine, although not all of them contributed to analyses. Three studies (<a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>; <a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a>; <a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>) did not report the age or sex, or both, of participants, but in the remaining studies the mean age was 52 to 59 years (range 20 to 84 years), and the majority of participants were female. </p> <p>A wide range of carbamazepine doses, ranging from 100 mg to 2400 mg daily, were used in the studies. Cross‐over studies predominated; only one had a parallel group design (<a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a>). Most of the studies were of short duration, lasting four weeks or less. Pain conditions studied were trigeminal neuralgia, painful diabetic neuropathy, and post stroke pain. </p> <p>Many of the studies were relatively old, with five published in the 1960s. Only one study (<a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a>) has been published in the last ten years. A consequence of the age of the studies is that outcomes ‐ pain, adverse event, and discontinuation ‐ were reported inconsistently. Pooling of trial data in meta‐analyses was therefore problematical, because few studies reported the same outcomes in the same way in the same condition. </p> <p>Details of included studies are given in the '<a href="./references#CD005451-sec-0108" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD005451-sec-0063"> <h4 class="title">Excluded studies</h4> <p>Five studies that were included in the earlier reviews are now excluded:</p> <p> <ul id="CD005451-list-0009"> <li> <p>one in acute herpes zoster (<a href="./references#CD005451-bbs2-0015" title="KeczkesK , BasheerAM . Do corticosteroids prevent post‐herpetic neuralgia?. British Journal of Dermatology1980;102:551‐5. ">Keczkes 1980</a>) due to the change of title to chronic pain and it was probably not blinded, </p> </li> <li> <p>one in postherpetic neuralgia (<a href="./references#CD005451-bbs2-0013" title="GersonGR , JonesRB , LuscombeDK . Studies on the concomitant use of carbamazepine and clomipramine for the relief of post‐herpetic neuralgia. Postgraduate Medical Journal1977;53:104‐9. ">Gerson 1977</a>) because it was not blinded, and </p> </li> <li> <p>three in trigeminal neuralgia: one (<a href="./references#CD005451-bbs2-0018" title="RasmussenP , RiishedeJ . Facial pain treated with carbamazepin (Tegretol). Acta Neurologica Scandinavica1970;46:385‐408. ">Rasmussen 1970</a>) because it was only single blind, and two (<a href="./references#CD005451-bbs2-0019" title="RockliffBW , DavisEH . Controlled sequential trials of Carbamazepine in trigeminal neuralgia. Archives of Neurology1966;15:129‐36. ">Rockliff 1966</a>; <a href="./references#CD005451-bbs2-0024" title="VilmingST , LybergT , LatasteX . Tizanidine in the management of trigeminal neuralgia. Cephalalgia1986;6:181‐2. ">Vilming 1986</a>) because they had fewer than 10 participants per treatment arm. </p> </li> </ul> </p> <p>Details of included studies are given in the '<a href="./references#CD005451-sec-0109" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD005451-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Out of a maximum of five points, two studies scored 5 points, five scored 4 points, one scored 3 points, and two scored 2 points on the Oxford Quality Scale. Points were lost due to failure to adequately report withdrawals or details of the randomisation and blinding processes. Scores for individual trials are reported in the notes section of '<a href="./references#CD005451-sec-0108" title="">Characteristics of included studies</a>' table. </p> <p>A risk of bias table was completed for randomisation, allocation concealment and blinding (<a href="#CD005451-fig-0002">Figure 2</a>; <a href="#CD005451-fig-0003">Figure 3</a>). All the included studies were judged to be at high risk of bias from at least one of three potential sources relating to size, duration, and outcome: </p> <div class="figure" id="CD005451-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005451-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005451-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005451-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p><b>Size</b>. Treatment group sizes were small, ranging from a maximum of 12 to 66 (mean 33, median 33 for carbamazepine). Small studies can be associated with larger treatment effects than bigger studies (<a href="./references#CD005451-bbs2-0035" title="CounsellCE , ClarkeMJ , SlatteryJ , SandercockPA . The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?. BMJ1994;309(6970):1677‐81. ">Counsell 1994</a>; <a href="./references#CD005451-bbs2-0069" title="MooreRA , GavaghanD , TramerMR , CollinsSL , McQuayHJ . Size is everything‐‐large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998a</a>; <a href="./references#CD005451-bbs2-0070" title="MooreRA , TramerMR , CarrollD , WiffenPJ , McQuayHJ . Quantitative systematic review of topically applied non‐steroidal anti‐inflammatory drugs. BMJ1998;316(7128):333‐8. ">Moore 1998b</a>; <a href="./references#CD005451-bbs2-0087" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nuesch 2010</a>). </p> <p><b>Duration</b>. Studies were of generally of short duration, with individual treatment periods ranging from five‐days in a straightforward cross‐over study (<a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>) to 42 months in a partial cross‐over study in which participants stayed on the first treatment for a minimum of two weeks and switched only if or when treatment was 'unsatisfactory' (<a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>). One study (<a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a>) used eight‐week treatment periods and three studies (<a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a>; <a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>; <a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>) used four‐week periods, with the remainder using 5 to 14 day periods. Chronic pain studies of six weeks or less have been shown to manifest greater treatment effects than those of eight weeks or more (<a href="./references#CD005451-bbs2-0074" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2009;Online:April 12. [DOI: 10.1136/ard.2009.107805] ">Moore 2009b</a>). </p> <p><b>Outcome</b>. A variety of different pain outcomes was reported, including average pain scores, raw individual pain scores (though not always complete), dichotomous outcomes such as the proportion with any improvement or benefit, including scores (like global impression of change) equivalent to IMMPACT outcomes of moderate or substantial benefit (<a href="./references#CD005451-bbs2-0039" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain2008;9(2):105‐21. ">Dworkin 2008</a>); some studies gave little or no indication of how many patients benefited from treatment. Four studies reported only group mean pain scores (<a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a>; <a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a>; <a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>) or a measure of 'upgrading', rather than absolute pain scores or amount of change (<a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a>). Higher levels of benefit (e.g. ≥ 50% pain relief rather than any pain relief) result in higher NNTs (<a href="./references#CD005451-bbs2-0074" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2009;Online:April 12. [DOI: 10.1136/ard.2009.107805] ">Moore 2009b</a>). </p> <p>None of the included studies mentioned how missing data were handled, for example using last observation carried forward or baseline observation carried forward imputation for participants who withdrew from the studies. Some studies may have analysed only those participants who completed the study, or both phases of a cross‐over study. </p> <p>Intention‐to‐treat analysis was not carried out and patients who dropped out of studies were not included in the analysis. This is likely to be the source of additional bias. </p> <p>Exaggeration of treatment effects in cross‐over trials compared with parallel group designs has been seen in some circumstances (<a href="./references#CD005451-bbs2-0057" title="KhanKS , DayaS , JadadA . The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine1996;156(6):661‐6. ">Khan 1996</a>), but it is unclear whether this is a general effect (<a href="./references#CD005451-bbs2-0041" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [Online ISSN: 1464‐3685; Print ISSN: 0300‐5771] ">Elbourne 2002</a>). The predominance of cross‐over trials in this review has to be considered as a possible source of additional bias. In these circumstances, caution is needed in interpreting the data as far as efficacy is concerned. In particular, meaningful comparison of efficacy with other interventions is not possible. </p> </section> <section id="CD005451-sec-0065"> <h3 class="title" id="CD005451-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD005451-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>Ten studies were suitable for inclusion. Studies enrolled participants with trigeminal neuralgia, diabetic neuropathy, or post stroke pain. There were no studies investigating carbamazepine in other neuropathic pain conditions or in fibromyalgia. Details of results in individual studies are presented in <a href="./appendices#CD005451-sec-0097">Appendix 4</a>. </p> <section id="CD005451-sec-0066"> <h4 class="title">Trigeminal neuralgia</h4> <p>Five studies of carbamazepine in trigeminal neuralgia were included. One of these (<a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>) also recruited some participants with other neuralgias; 30 of 42 participants had trigeminal neuralgia. </p> <p>There was no first or second tier evidence of efficacy.</p> <section id="CD005451-sec-0067"> <h5 class="title">Third tier evidence.</h5> <p>Three studies were placebo‐controlled (<a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a>; <a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>; <a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>). Using dose titration to a maximum daily dose of 1000 mg, 19/27 participants had a complete or very good response with carbamazepine compared with minimal or no response with placebo on five days' treatment in a subset of patients with trigeminal neuralgia (<a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>). Again using dose titration and a cross‐over design, but to a maximum daily dose of 2400 mg, 15/20 participants randomised to initial carbamazepine had a good or excellent response after 14 days' treatment, compared with 6 of 24 reporting good or excellent response who started on placebo (<a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>). There were too few data for analysis. </p> <p>A study by <a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a> reported results by the number of changes in the pain score; this study has been removed from the analyses in this version as the numbers presented in the paper are events rather than patient data. It had claimed a mean fall in maximum pain intensity of 58% after two weeks with carbamazepine 400 to 800 mg daily compared to 26% with placebo. </p> <p>Two active controlled studies were included. <a href="./references#CD005451-bbs2-0007" title="LindstromP , LindblomU . The analgesic effect of tocainide in trigeminal neuralgia. Pain1987;28:45‐50. [DOI: 10.1016/0304‐3959(87)91058‐X] ">Lindstrom 1987</a> compared carbamazepine (maximum tolerated dose) with tocainide (an antiarrhythmic drug; 20 mg/kg/day divided into three doses). All participants had baseline pain scores without treatment of ≥4/10. There was no difference between the treatments; 7/12 and 6/12 participants treated with carbamazepine and tocainide respectively had mean pain scores of ≤ 3/10 (no worse than mild pain) in the last 10 days of a two‐week treatment period. Only one participant responded to carbamazepine, but not tocainide. </p> <p><a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a> compared carbamazepine (titrated to maximum 1200 mg/day) with pimozide (an antipsychotic drug; titrated to maximum 12 mg/day) over eight weeks. All 24 participants treated with pimizole, and 14/24 treated with carbamazepine in the first period of treatment "eventually improved", with maximal improvement after 6 weeks of treatment. Results for the second period of the cross‐over study were similar. </p> </section> </section> <section id="CD005451-sec-0068"> <h4 class="title">Diabetic neuropathy</h4> <p>Four studies evaluated carbamazepine in diabetic neuropathy (<a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>; <a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a>; <a href="./references#CD005451-bbs2-0009" title="RullJ , QuibreraR , Gonzalez‐MillanH , Lozano CastenadaO . Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double‐blind crossover study. Diabetologia1969;5:215‐20. ">Rull 1969</a>; <a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>). </p> <p>There was no first or second tier evidence of efficacy.</p> <section id="CD005451-sec-0069"> <h5 class="title">Third tier evidence</h5> <p>Two studies were placebo controlled (<a href="./references#CD005451-bbs2-0009" title="RullJ , QuibreraR , Gonzalez‐MillanH , Lozano CastenadaO . Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double‐blind crossover study. Diabetologia1969;5:215‐20. ">Rull 1969</a>; <a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>). In a complicated three‐way cross‐over, <a href="./references#CD005451-bbs2-0009" title="RullJ , QuibreraR , Gonzalez‐MillanH , Lozano CastenadaO . Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double‐blind crossover study. Diabetologia1969;5:215‐20. ">Rull 1969</a> found that, using the top two levels of pain improvement (3 points or better out of 5), in the first two of three cross‐over periods for each group, 17/30 improved with carbamazepine and 2/30 for placebo, over two weeks. The other study (<a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>) reported only on preferences after one week of treatment with carbamazepine and placebo; 24/40 preferred carbamazepine, 14/40 preferred placebo, and 2/40 had no preference. </p> <p>Two active controlled studies met the inclusion criteria. One compared carbamazepine 200 mg to a nortriptyline 10 mg plus fluphenazine 0.5 mg combination over four weeks (<a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>). No significant difference was found between carbamazepine and the nortriptyline combination; both treatments improved paraesthesia and pain. <a href="./references#CD005451-bbs2-0003" title="JiaHai‐yun , LiQu‐fu , SongDian‐ping , LiuYou‐ping , RanXing‐wu , et al. Effects of Venlafaxine and Carbamazepine for painful peripheral diabetic neuropathy: A randomized double blind and double dummy controlled multicenter trial. Chinese Journal of Evidence Based Medicine2006;6:321‐7. ">Jia 2006</a> compared venlafaxine with carbamazepine over two weeks in 132 participants, with both drugs given at fixed and relatively low dose. Both drugs demonstrated effect with venlafaxine showing a somewhat larger mean effect. </p> </section> </section> <section id="CD005451-sec-0070"> <h4 class="title">Post stroke pain</h4> <p>There was no first or second tier evidence.</p> <section id="CD005451-sec-0071"> <h5 class="title">Third tier evidence</h5> <p>A cross‐over study compared carbamazepine, amitriptyline, and placebo, with a treatment duration of four weeks for each (<a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>). Global report of any improvement occurred in 10 of 15 on amitriptyline, 5 of 15 on carbamazepine, and 1 of 15 on placebo. </p> </section> </section> <section id="CD005451-sec-0072"> <h4 class="title">Overall estimation of efficacy</h4> <p>Although we specified that we would analyse different pain conditions separately, because carbamazepine is such a widely used drug for neuropathic pain (particularly trigeminal neuralgia) and because we found so little evidence, we did carry out a post‐hoc analysis combining pain conditions to look for a direction of effect. </p> <p>Four studies (188 participants) compared carbamazepine with placebo and provided dichotomous outcomes equivalent to the IMMPACT substantial improvement (<a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>; <a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>; <a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>; <a href="./references#CD005451-bbs2-0009" title="RullJ , QuibreraR , Gonzalez‐MillanH , Lozano CastenadaO . Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double‐blind crossover study. Diabetologia1969;5:215‐20. ">Rull 1969</a>). Carbamazepine at any dose was consistently better than placebo (<a href="#CD005451-fig-0004">Figure 4</a>) and overall 61% (56/92) of participants improved with carbamazepine compared with 9% (9/96) with placebo. The RR was 6.5 (3.4 to 12.2), and the NNT 1.9 (1.6 to 2.5) (<a href="./references#CD005451-fig-0006" title="">Analysis 1.1</a>; <a href="#CD005451-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD005451-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Four studies showing percentage improvement (any definition) with carbamazepine (any dose) and placebo. Size of the study is proportional to the size of the symbol (inset scale). Yellow symbols = trigeminal neuralgia , blue = painful diabetic neuropathy, red = post stroke pain" data-id="CD005451-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Four studies showing percentage improvement (any definition) with carbamazepine (any dose) and placebo. Size of the study is proportional to the size of the symbol (inset scale). Yellow symbols = trigeminal neuralgia , blue = painful diabetic neuropathy, red = post stroke pain </p> </div> </div> </div> <div class="figure" id="CD005451-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Carbamazepine in neuropathic pain, outcome: 1.1 Any pain improvement." data-id="CD005451-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carbamazepine in neuropathic pain, outcome: 1.1 Any pain improvement. </p> </div> </div> </div> </section> <section id="CD005451-sec-0073"> <h4 class="title">Withdrawals</h4> <p>Eight studies provided information on adverse event withdrawals with carbamazepine (<a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a>; <a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>; <a href="./references#CD005451-bbs2-0004" title="KillianJM , FrommGH . Carbamazepine in the treatment of neuralgia. Use and side effects. Archives of Neurology1968;19:129‐36. ">Killian 1968</a>; <a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a>; <a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>; <a href="./references#CD005451-bbs2-0007" title="LindstromP , LindblomU . The analgesic effect of tocainide in trigeminal neuralgia. Pain1987;28:45‐50. [DOI: 10.1016/0304‐3959(87)91058‐X] ">Lindstrom 1987</a>; <a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>; <a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>). In these studies, 8/268 (3%) of participants withdrew because of adverse events with carbamazepine, compared with 0/255 with placebo. </p> </section> <section id="CD005451-sec-0074"> <h4 class="title">At least one adverse event</h4> <p>Four studies provided information on participants experiencing at least one adverse event (<a href="./references#CD005451-bbs2-0001" title="CampbellFG , GrahamJG , ZilkhaKJ . Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. Journal of Neurology, Neurosurgery and Psychiatry1966;29:265‐7. ">Campbell 1966</a>; <a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a>; <a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a>; <a href="./references#CD005451-bbs2-0010" title="WiltonTD . Tegretol in the Treatment of Diabetic Neuropathy. S‐A Mediese Tydskrif1974;48:869‐72. ">Wilton 1974</a>). Adverse event experience was more common with carbamazepine (66% of participants) than placebo (27%), RR 2.4 (1.9 to 3.2), NNH 2.6 (2.1 to 3.5). </p> </section> <section id="CD005451-sec-0075"> <h4 class="title">Serious adverse events</h4> <p>Serious adverse events were not reported consistently, and that included the absence of negative statements that there were no serious adverse events. Only one study (<a href="./references#CD005451-bbs2-0002" title="Gomez‐PerezF , ChozaR , RiosJM , RezaA , HuertaE , AguilarCA , RullJA . Nortriptyline‐Fluphenazine vs Carbamazepine in the symptomatic treatment of diabetic neuropathy. Archives of Medical Research1996;27(4):525‐9. ">Gomez‐Perez 1996</a>) reported an adverse event as serious, a case of upper gastrointestinal bleeding thought to be associated with alcohol rather than carbamazepine. Rashes associated with carbamazepine were reported in two participants in <a href="./references#CD005451-bbs2-0009" title="RullJ , QuibreraR , Gonzalez‐MillanH , Lozano CastenadaO . Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double‐blind crossover study. Diabetologia1969;5:215‐20. ">Rull 1969</a>; these may be considered serious because of association with Stevens‐Johnson syndrome. </p> </section> <section id="CD005451-sec-0076"> <h4 class="title">Deaths</h4> <p>Four deaths occurred on treatment with carbamazepine, all in one study (<a href="./references#CD005451-bbs2-0008" title="NicolCF . A four year double blind study of tegretol in facial pain. Headache1969;9:54‐7. ">Nicol 1969</a>), which had the longest follow‐up; two participants died suddenly, presumably of cardiovascular disease, one had a brain tumour, and one died of progressive debilitating disease. </p> </section> <section id="CD005451-sec-0077"> <h4 class="title">Specific adverse effects</h4> <p>Specific adverse events reported at high incidence (&gt; 10%) included giddiness, dizziness, unsteadiness, and somnolence. These were not reported in sufficient detail to be combined, but the incidence of somnolence and dizziness was as high as 40‐60% with carbamazepine. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005451-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005451-sec-0078">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005451-sec-0140">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005451-sec-0078"></div> <p>Much has been written about how to justify the use of our long‐established medical interventions. While the randomised controlled trial (RCT) is the gold standard for the assessment of health care technologies and interventions (<a href="./references#CD005451-bbs2-0038" title="Advisory Group on Health Technology Assessment. Assessing the Effects of Health Technologies. London: Department of Health, 1992. ">DOH 1992</a>), buttressed by double blinding when the outcome measures are subjective (<a href="./references#CD005451-bbs2-0033" title="ColditzGA , MillerJN , MostellerF . How study design affects outcomes in comparisons of therapy. Statistical Methods in Medical Research1989;8:441‐54. ">Colditz 1989</a>; <a href="./references#CD005451-bbs2-0093" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Failure to conceal treatment allocation schedules in trials influences estimates of treatment effects. Controlled Clinical Trials1994;15:63‐64S. ">Schulz 1994</a>; <a href="./references#CD005451-bbs2-0103" title="TurnerJA , DeyoRA , LoeserJD , VonKorffM , FordyceWE . The importance of placebo effects in pain treatment and research. JAMA1994;271(20):1609‐14. [ISSN 0098‐7484] ">Turner 1994</a>), the fact remains that many interventions are time‐honoured rather than RCT‐honoured. On whom then does the burden of proof fall? (<a href="./references#CD005451-bbs2-0040" title="EddyDM . Three battles to watch in the 1990s. JAMA1993;270:520‐6. ">Eddy 1993</a>). The aim of this systematic review was to review the effectiveness and safety of the antiepileptic drug carbamazepine in the management of neuropathic pain and fibromyalgia. Since the first version of this review, gabapentin has become established as a treatment for neuropathic pain, and is now licensed for this indication in a number of countries. The problem is that there is very little good evidence to support the received wisdom regarding carbamazepine and its use in neuropathic pain or fibromyalgia generally, or even in trigeminal neuralgia, where response to carbamazepine has in the past been regarded as almost pathognomic. </p> <p>More recent antiepileptic drugs have good evidence of effect, as with gabapentin (<a href="./references#CD005451-bbs2-0080" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 201, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a>), pregabalin (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>), or oxcarbazepine (<a href="./references#CD005451-bbs2-0110" title="ZhouM , ChenN , HeL , YangM , ZhuC , WuF . Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD007963.pub2] ">Zhou 2013</a>), or good evidence of lack of effect as with lamotrigine (<a href="./references#CD005451-bbs2-0105" title="WiffenPJ , DerryS , MooreRA . Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD006044.pub4] ">Wiffen 2013b</a>) and topiramate (<a href="./references#CD005451-bbs2-0106" title="WiffenPJ , DerryS , LunnMP , MooreRA . Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008314.pub3] ">Wiffen 2013c</a>). An updated version of Gabapentin is currently awaiting publication(April 2014) and an overview of these medicines titled 'Antiepileptic drugs for neuropathic pain and fibromyalgia‐an overview of Cochrane reviews' has been recently published (<a href="./references#CD005451-bbs2-0104" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013a</a>). </p> <section id="CD005451-sec-0079"> <h3 class="title" id="CD005451-sec-0079">Summary of main results</h3> <p>Carbamazepine generally provided better pain relief than placebo in a comparison that included three different chronic neuropathic pain conditions (trigeminal neuralgia, painful diabetic neuropathy, and central post stroke pain). There was some indication of pain improvement over mainly the short term, but with poorly defined outcomes, in fewer than 200 participants (less than a tenth of the number of participants available for one dose of pregabalin, for instance; (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>)). The NNH for any adverse event was 4, though again reporting was neither consistent nor complete. </p> <p>What we have is an indication that carbamazepine can produce good levels of pain relief for some patients with distressing chronic painful conditions. </p> </section> <section id="CD005451-sec-0080"> <h3 class="title" id="CD005451-sec-0080">Overall completeness and applicability of evidence</h3> <p>The evidence is far from complete, and any assessment of applicability resides less with the evidence than the long experience of using the drug in neuropathic pain. The major problems with the amount and quality of the evidence available include: </p> <p> <ul id="CD005451-list-0010"> <li> <p>limited size, with all but one study involving fewer than 60 participants;</p> </li> <li> <p>short duration, with all but two studies being four weeks or less in treatment duration;</p> </li> <li> <p>inadequate outcomes, with inconsistent reporting not allowing outcomes equivalent to IMMPACT outcomes of at least moderate benefit to be assumed; </p> </li> <li> <p>incomplete outcome assessment, with studies reporting on completers only, or not reporting on imputation methods. </p> </li> </ul> </p> <p>Poor quality reporting limited the ability to combine data, because many studies reported insufficient information, used a variety of different outcome measures, and several studies used variable dosing. Although the authors of the original reports were originally contacted by letter, not all of them replied, and of those who did, only <a href="./references#CD005451-bbs2-0006" title="LeijonG , BoivieJ . A controlled trial of amitriptyline and carbamazepine in central post stroke pain. Acta Nuerologica Scandanavica1988;77 (Suppl 116):102. LeijonG , BoivieJ . Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain1989;36:27‐36. ">Leijon 1989</a> was able to provide additional data. </p> <p>Doses of carbamazepine used in some of the studies were small; Gomez Perez, for example, used 200 mg daily, which while effective in some is not effective in all (<a href="./references#CD005451-bbs2-0100" title="TaylorJC , BrauerS , EspirML . Long‐term treatment of trigeminal neuralgia with carbamazepine. Postgraduate Medical Journal1981;57(663):16‐8. ">Taylor 1981</a>). Dose escalation was rapid in some studies, potentially resulting in adverse effects. Although carbamazepine takes two to four days to achieve its maximum effect, auto induction of enzymes that metabolise the drug, which is complete at three weeks, often means that late dose increases are needed. These factors are largely ignored, and this limits the applicability of the available evidence. </p> <p>These studies do not provide adequate information about adverse events, and in particular serious adverse events. This is of particular importance for serious cutaneous adverse events in some parts of the world. A strong genetic association between HLA‐B*1502 and carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis has been shown in Han Chinese (<a href="./references#CD005451-bbs2-0032" title="ChungWH , HungSI , ChenYT . Genetic predisposition of life‐threatening antiepileptic‐induced skin reactions. Expert Opinion on Drug Safety2010;9:15‐21. ">Chung 2010</a>), Indian (<a href="./references#CD005451-bbs2-0066" title="MehtaTY , PrajapatiLM , MittalB , JoshiCG , ShethJJ , PatelDB , et al. Association of HLA‐B*1502 allele and carbamazepine‐induced Stevens‐Johnson syndrome among Indians. Indian journal of dermatology, venereology and leprology2009;75:579‐82. ">Mehta 2009</a>), and Thai (<a href="./references#CD005451-bbs2-0099" title="TassaneeyakulW , TiamkaoS , JantararoungtongT , ChenP , LinSY , ChenWH , et al. Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia2010;51(5):926‐30. [DOI: 10.1111/j.1528‐1167.2010.02533] ">Tassaneeyakul 2010</a>) populations, and Asian populations generally may be more susceptible. While the frequency of this allele is low in Europe, its frequency in Asian populations is 5‐10% (<a href="./references#CD005451-bbs2-0032" title="ChungWH , HungSI , ChenYT . Genetic predisposition of life‐threatening antiepileptic‐induced skin reactions. Expert Opinion on Drug Safety2010;9:15‐21. ">Chung 2010</a>). Carbamazepine is the most common causative agent for Stevens‐Johnson syndrome and toxic epidermal necrolysis in Europe (8% of total), rising to 26% in Taiwan, 36% in Malaysia and 28% in Singapore (<a href="./references#CD005451-bbs2-0032" title="ChungWH , HungSI , ChenYT . Genetic predisposition of life‐threatening antiepileptic‐induced skin reactions. Expert Opinion on Drug Safety2010;9:15‐21. ">Chung 2010</a>). </p> <p>There is also an interaction between carbamazepine and warfarin metabolism which can be of major clinical importance (<a href="./references#CD005451-bbs2-0049" title="HermanD , LocatelliI , GrabnarI , PeternelP , StegnarM , LainscakM , et al. The influence of co‐treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. European Journal of Clinical Pharmacology2006;62(4):291‐6. [DOI: 10.1007/s00228‐006‐0104‐4] ">Herman 2006</a>). If treatment with carbamazepine cannot be avoided, patients taking warfarin should be frequently monitored, especially when initiating or stopping carbamazepine therapy. </p> </section> <section id="CD005451-sec-0081"> <h3 class="title" id="CD005451-sec-0081">Quality of the evidence</h3> <p>Studies were small, short, and had inadequate definitions of benefit, plus incomplete reporting. For each of these there is evidence that they could be the source of systematic bias, and this significantly reduces the weight we can give such evidence as we have. In particular, it limits comparability of carbamazepine results with results for other interventions obtained from larger, longer, and better studies and meta‐analyses. </p> <p>In order to be sure that carbamazepine works in chronic painful conditions and to be confident of the magnitude of the effect, the ideal would be several large randomised double blind studies comparing carbamazepine at sensible doses with placebo, over 8 to 12 weeks, and using IMMPACT outcomes (perhaps at least moderate improvement or benefit) or their equivalent in each of several clinical conditions, as we have for pregabalin, for example (<a href="./references#CD005451-bbs2-0073" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009a</a>). We actually have only one study of adequate duration; <a href="./references#CD005451-bbs2-0005" title="LechinF , van derDijsB , LechinME , AmatJ , LechinAE , CabreraA , et al. Pimozide therapy for trigeminal neuralgia. Archives of Neurology1989;46:960‐3. ">Lechin 1989</a> enrolled 59 participants with trigeminal neuralgia, had a quality score of 4 of 5, but reported only an undefined improvement for only 48 of 59 participants randomised (1 lost to follow‐up and 10 protocol deviations). </p> </section> <section id="CD005451-sec-0082"> <h3 class="title" id="CD005451-sec-0082">Potential biases in the review process</h3> <p>Criteria for assessing potential biases in chronic pain are becoming more stringent as new biases are being discovered (<a href="./references#CD005451-bbs2-0077" title="MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. ‘‘Evidence” in chronic pain – establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] ">Moore 2010b</a>; <a href="./references#CD005451-bbs2-0082" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012b</a>). Potential biases in the review process derive from including studies with the potential for bias, though the review has sought to highlight the potential for bias when it occurs. </p> <p>Using only criteria of sufficient stringency to avoid all these potential biases would reduce the pool of included studies to nil, which, given that carbamazepine is used to treat neuropathic pain, is less than helpful. </p> </section> <section id="CD005451-sec-0083"> <h3 class="title" id="CD005451-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>The results of this review are generally in agreement with the previous version. We are not aware of any other systematic reviews specifically concerning carbamazepine, but a broad overview of interventions for neuropathic pain (<a href="./references#CD005451-bbs2-0042" title="FinnerupNB , OttoM , McQuayHJ , JensenTS , SindrupSH . Algorithm for neuropathic pain treatment: an evidence based proposal. Pain2005;118(3):289‐305. [DOI: 10.1016/j.pain.2005.08.013] ">Finnerup 2005</a>) had a combined NNT for efficacy of 2.0 (1.6 to 2.5), similar to our estimate of 1.7 (1.5 to 2.0). The source of the small difference cannot be ascertained from details provided. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005451-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005451-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005451-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005451-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Four studies showing percentage improvement (any definition) with carbamazepine (any dose) and placebo. Size of the study is proportional to the size of the symbol (inset scale). Yellow symbols = trigeminal neuralgia , blue = painful diabetic neuropathy, red = post stroke pain" data-id="CD005451-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Four studies showing percentage improvement (any definition) with carbamazepine (any dose) and placebo. Size of the study is proportional to the size of the symbol (inset scale). Yellow symbols = trigeminal neuralgia , blue = painful diabetic neuropathy, red = post stroke pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Carbamazepine in neuropathic pain, outcome: 1.1 Any pain improvement." data-id="CD005451-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Carbamazepine in neuropathic pain, outcome: 1.1 Any pain improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbamazepine in neuropathic pain, Outcome 1 Any pain improvement." data-id="CD005451-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Carbamazepine in neuropathic pain, Outcome 1 Any pain improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references#CD005451-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005451-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/urn:x-wiley:14651858:media:CD005451:CD005451-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_t/tCD005451-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Carbamazepine in neuropathic pain, Outcome 2 At least 1 adverse event." data-id="CD005451-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Carbamazepine in neuropathic pain, Outcome 2 At least 1 adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references#CD005451-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/media/CDSR/CD005451/image_n/nCD005451-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005451-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with placebo for chronic neuropathic pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: oral carbamazepine (</b> 100 mg to 2400 mg daily<b>)</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>NNT or NNH and/or relative effect (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> and studies</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Substantial" benefit</p> <p>At least 50% reduction in pain or equivalent</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>94 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>608 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.5 (3.4 to 12)</p> <p>NNT 1.9 (1.6 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188 participants,</p> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mixed conditions and doses, small studies of short duration, imputation not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Moderate" benefit</p> <p>At least 30% reduction in pain</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion below 30/100 mm on VAS</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient Global Impression of Change much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>270 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>660 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.4 (1.9 to 3.2)</p> <p>NNH 2.6 (2.1 to 3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346 participants,</p> <p>4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over studies</p> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse event withdrawals</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>30 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523 participants,</p> <p>8 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over studies</p> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 participants,</p> <p>2 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 participants</p> <p>1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denominator = all <b>potentially</b> exposed </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>NNT: number needed to treat for an additional beneficial effect: NNH: number needed to treat for an additional harmful effect; RR: risk ratio; VAS: visual analogue scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/full#CD005451-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005451-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carbamazepine in neuropathic pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Any pain improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.46 [3.43, 12.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trigeminal neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.02 [2.82, 12.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.5 [2.15, 33.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Central post stroke pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.66, 37.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At least 1 adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.85, 3.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Carbamazepine in neuropathic pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005451.pub3/references#CD005451-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005451.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005451-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005451-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005451-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005451-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005451-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005451-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005451\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005451\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005451\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005451\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005451\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005451.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005451.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005451.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005451.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005451.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717915793"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005451.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717915797"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005451.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc3977afb9377',t:'MTc0MDcxNzkxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 